Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 14, 2013 - Issue 3
Submit an article Journal homepage
973
Views
32
CrossRef citations to date
0
Altmetric
Original Research

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

Yuki FujiiNihon University School of Medicine, Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, 30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan+81 3 3972 8111; +81 3 3972 8311; [email protected]
,
Masanori AbeNihon University School of Medicine, Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, 30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan+81 3 3972 8111; +81 3 3972 8311; [email protected]
, MD,
Terumi HiguchiKeiai Hospital, Department of Nephrology, Tokyo, Japan
,
Mari MizunoKeiai Hospital, Department of Nephrology, Tokyo, Japan
,
Hiroko SuzukiNihon University School of Medicine, Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, 30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan+81 3 3972 8111; +81 3 3972 8311; [email protected]
,
Shiro MatsumotoNihon University School of Medicine, Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, 30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan+81 3 3972 8111; +81 3 3972 8311; [email protected]
,
Midori ItoNihon University School of Medicine, Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, 30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan+81 3 3972 8111; +81 3 3972 8311; [email protected]
,
Noriaki MaruyamaNihon University School of Medicine, Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, 30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan+81 3 3972 8111; +81 3 3972 8311; [email protected]
,
Kazuyoshi OkadaNihon University School of Medicine, Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, 30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan+81 3 3972 8111; +81 3 3972 8311; [email protected]
&
Masayoshi SomaNihon University School of Medicine, Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, 30-1, Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan+81 3 3972 8111; +81 3 3972 8311; [email protected];Nihon University School of Medicine, Division of General Medicine, Department of Internal Medicine, Tokyo, Japan
 show all
Pages 259-267 | Published online: 07 Jan 2013

Citations (32)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Hiroyuki Ito, Mariko Abe, Shinichi Antoku, Takashi Omoto, Masahiro Shinozaki, Shinya Nishio, Mizuo Mifune & Michiko Togane. (2015) Comparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment – retrospective observation study of Japanese patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 16:3, pages 289-296.
Read now
André J Scheen. (2015) A review of gliptins for 2014. Expert Opinion on Pharmacotherapy 16:1, pages 43-62.
Read now
Daniel Q Holland & Joshua J Neumiller. (2014) Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 7, pages 277-288.
Read now
Janet B. McGill. (2014) Anti-Diabetes Therapy: Safety Considerations for Patients With Impaired Kidney Function. Postgraduate Medicine 126:3, pages 161-171.
Read now
Yutaka Seino & Daisuke Yabe. (2014) Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 15:6, pages 851-863.
Read now

Articles from other publishers (25)

Shih-Hsiang Ou, Hsin-Yu Chen, Nai-Wen Fang, Chun-Hao Yin, Chien-Liang Chen & Jin-Shuen Chen. (2021) Effect of anti-diabetic drugs in dialysis patients with diabetes: a nationwide retrospective cohort study. Cardiovascular Diabetology 20:1.
Crossref
Kohei Kaku, Koichi Kisanuki, Mari Shibata & Takashi Oohira. (2019) Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. Drug Safety 42:11, pages 1311-1327.
Crossref
Konstantinos Makrilakis. (2019) The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect. International Journal of Environmental Research and Public Health 16:15, pages 2720.
Crossref
Clara García-Carro, Ander Vergara, Irene Agraz, Conxita Jacobs-Cachá, Eugenia Espinel, Daniel Seron & María Soler. (2019) The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. Journal of Clinical Medicine 8:6, pages 864.
Crossref
Wendy L. St. Peter, Lori Wazny & Joanna Q. Hudson. 2019. Chronic Kidney Disease, Dialysis, and Transplantation. Chronic Kidney Disease, Dialysis, and Transplantation 250 272.e5 .
Deborah A. Chon, Rachael T. Oxman, Rashmi S. Mullur & Jane Eileen Weinreb. 2019. Endocrine Disorders in Kidney Disease. Endocrine Disorders in Kidney Disease 49 74 .
Polly A. Bittle. (2017) The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease. The Nurse Practitioner 42:6, pages 31-38.
Crossref
Vishnu Garla, Licy Yanes-Cardozo & Lillian F. Lien. (2017) Current therapeutic approaches in the management of hyperglycemia in chronic renal disease. Reviews in Endocrine and Metabolic Disorders 18:1, pages 5-19.
Crossref
Naoshi Yoshida, Tetsuya Babazono, Ko Hanai & Yasuko Uchigata. (2016) Switching from subcutaneous insulin injection to oral vildagliptin administration in hemodialysis patients with type 2 diabetes: a pilot study. International Urology and Nephrology 48:8, pages 1349-1355.
Crossref
Masanori Abe, Terumi Higuchi, Masari Moriuchi, Masahiro Okamura, Ritsukou Tei, Chinami Nagura, Hiroyuki Takashima, Fumito Kikuchi, Hyoe Tomita & Kazuyoshi Okada. (2016) Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial. Diabetes Research and Clinical Practice 116, pages 244-252.
Crossref
G. Penno, M. Garofolo & S. Del Prato. (2016) Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrition, Metabolism and Cardiovascular Diseases 26:5, pages 361-373.
Crossref
Jun-ichiro Mera, Eiko Okada, Masumi Okuda, Tatsuru Ota, Shigeru Sibata & Shunya Uchida. (2015) Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis. Journal of Diabetes & Metabolic Disorders 14:1.
Crossref
Suzanne M. Boyle, Barbara Simon & Sidney M. Kobrin. (2015) Antidiabetic Therapy in End-Stage Renal Disease. Seminars in Dialysis 28:4, pages 337-344.
Crossref
Masanori Abe & Kamyar Kalantar-Zadeh. (2015) Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nature Reviews Nephrology 11:5, pages 302-313.
Crossref
Gillian M. Keating. (2015) Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:7, pages 777-796.
Crossref
Kunitoshi Iseki. (2015) Control of hypertension and survival in haemodialysis patients. Nephrology 20:2, pages 49-54.
Crossref
André J. Scheen. (2014) Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes. Clinical Pharmacokinetics 54:1, pages 1-21.
Crossref
T. M. E. Davis. (2014) Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes, Obesity and Metabolism 16:10, pages 891-899.
Crossref
P. Arnouts, D. Bolignano, I. Nistor, H. Bilo, L. Gnudi, J. Heaf & W. v. Biesen. (2013) Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrology Dialysis Transplantation 29:7, pages 1284-1300.
Crossref
Anne Marie Liles. (2014) Medication Pitfalls in the CKD Clinic: Case Presentations. Advances in Chronic Kidney Disease 21:4, pages 349-354.
Crossref
Miyako Kishimoto & Mitsuhiko Noda. (2014) Glucose management in diabetic patients undergoing hemodialysis. Diabetology International 5:2, pages 84-91.
Crossref
Yuya Nakamura, Mayumi Tsuji, Hitomi Hasegawa, Kengo Kimura, Kiichiro Fujita, Michiyasu Inoue, Tatsuo Shimizu, Hiromichi Gotoh, Yoshikazu Goto, Masahiro Inagaki & Katsuji Oguchi. (2014) Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes. Hemodialysis International 18:2, pages 433-442.
Crossref
Yukie Kurokawa, Yasunori Iwata, Ken-ichiro Kato, Shinji Kitajima, Toshinari Takamura, Takashi Wada & Yoshitaka Koshino. (2014) The switch from insulin to vildagliptin in hemodialysis patients with diabetes. Nihon Toseki Igakkai Zasshi 47:9, pages 539-545.
Crossref
German Ramirez, Anthony D. Morrison & Polly A. Bittle. (2013) Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease. Endocrine Practice 19:6, pages 1025-1034.
Crossref
Junjie Zhu, Yangliang Ye, Mengmeng Ning, Attila Mándi, Ying Feng, Qingan Zou, Tibor Kurtán, Ying Leng & Jianhua Shen. (2013) Design, Synthesis, and Structure-Activity Relationships of 3,4,5-Trisubstituted 4,5-Dihydro-1,2,4-oxadiazoles as TGR5 Agonists. ChemMedChem 8:7, pages 1210-1223.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.